Importantly, the lack of correlation between BCAM and PD-L1 expression across cancer types indicates BCAM as an alternative prognostic marker and therapeutic target for patients less likely to benefit from PD-1/PD-L1 inhibitors. This evidence concerns the gene PDCD1 and cancer.